Communiqués de presse Archive - Page 4 of 21 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Provides Business and Corporate Update

OSE Immunotherapeutics and Boehringer Ingelheim expand collaboration to develop first-in-class treatments for cancer and cardio-renal-metabolic diseases

OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective

OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer

OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

OSE Immunotherapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis

OSE Immunotherapeutics to Host a Live Webcast to Discuss AbbVie Global Partnership On February 28, 2024, at 6:00 p.m. CET / 12:00 a.m. ET.

AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation

OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors

Précédent
1
2
3
4
5
6
7
8
9
…
21
Suivant